Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Allison Berger"'
Autor:
Hongru Zhang, Vivek S. Tomar, Jinyang Li, Raghavendra Basavaraja, Fangxue Yan, Jun Gui, Noreen McBrearty, Tara Lee Costich, Daniel P. Beiting, M. Andres Blanco, Jose R. Conejo-Garcia, Gurpanna Saggu, Allison Berger, Yulia Nefedova, Dmitry I. Gabrilovich, Serge Y. Fuchs
Publikováno v:
Cancer Immunol Res
Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a20922e070b73ffc8481106619e1a90b
https://europepmc.org/articles/PMC9722544/
https://europepmc.org/articles/PMC9722544/
Autor:
Jayaprakasam, Bolleddula, Hao, Chen, Lawrence, Cohen, Xiaofei, Zhou, Sandeepraj, Pusalkar, Allison, Berger, Farhad, Sedarati, Karthik, Venkatakrishnan, Swapan K, Chowdhury
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 50(7)
Metabolism and disposition of pevonedistat, an investigational, first-in-class inhibitor of the NEDD8-activating enzyme (NAE), were characterized in patients with advanced solid tumors after intravenous infusion of [
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Glen J. Weiss, John S. Kauh, Bruce J. Dezube, Jeffrey W. Clark, Roger B. Cohen, Devalingam Mahalingam, James M. Cleary, Hélène M. Faessel, Allison Berger, Michael D. Pickard, George Mulligan, Kristin E. Burke, R. Donald Harvey, Geoffrey I. Shapiro, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 22:847-857
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Autor:
Thea Kalebic, Neeraj Gupta, Lillian L. Siu, John S. Kauh, David Smith, Feng Gao, Ai Min Hui, Jeffrey R. Infante, Gordana Vlahovic, Allison Berger, Jianchang Lin, John A. Thompson, Deborah Berg, Guohui Liu, Stephen Tirrell, Daniel C. Sullivan, Alessandra Di Bacco
Publikováno v:
Investigational New Drugs
SummaryPurpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, i
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Paul G. Richardson, Alessandra Di Bacco, Andrew Dorner, Allison Berger, Deborah Ricci, Pieter Sonneveld, Erik Koenig, Robert Z. Orlowski, Jeśus F.San Miguel, Hugues Bernard, Edward A. Stadtmauer, William L. Trepicchio, David I. Lichter, Helgi van de Velde, Sundar Jagannath, Matthew Schu, Kenneth C. Anderson, Stephen J. Blakemore, Nibedita Chattopadhyay, Dixie Lee Esseltine, George Mulligan, Joseph B. Bolen, Rachel Neuwirth, Bin Li, Sagar Lonial, James R. Berenson
Publikováno v:
Blood, 123(5), 632-639. American Society of Hematology
Various translocations and mutations have been identified in myeloma, and certain aberrations, such as t(4;14) and del17, are linked with disease prognosis. To investigate mutational prevalence in myeloma and associations between mutations and patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc7a06d9996ee11f17c51fcbb70b586
https://europepmc.org/articles/PMC4123425/
https://europepmc.org/articles/PMC4123425/
Autor:
Kristin E. Burke, Doug Bowman, Arijit Chakravarty, Mark D. Fleming, Jeffrey Ecsedy, A. A. McDonald, Vaishali Shinde, Stephen Tirrell, Stephen J. Blakemore, Allison Berger
Publikováno v:
Veterinary pathology. 51(1)
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical models and clinical studies. Automated slide-scanning and advanced high-throughput image analysis software technologies have
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som